Telix Pharmaceuticals hits upgraded FY25 guidance on strong Q4 revenue
Make us a preferred source
Make us a preferred source on Google
The news: Telix Pharmaceuticals achieved its upgraded guidance as the company achieved “excellent sequential growth” during Q4, driven in part by the successful launch of prostate cancer imaging agent Gozellix.
The numbers: Telix achieved FY 2025 revenue of approximately USD804 million ($1.2 billion), in line with its upgraded guidance of USD800 million to USD820 million, up from USD770 million and USD800 million.
The company reported unaudited Q4 group revenue of USD208 million, up 46% year-on-year.
The context: Telix’s Precision Medicine business brought in roughly USD161 million, up 4% quarter-on-quarter, after launching Gozellix in the US following reimbursement by Centers for Medicare and Medicaid Services (CMS) from October last year.
Earlier on Tuesday Telix also confirmed that it has received clearance from the Chinese National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) to proceed with the filing of a drug application for its prostate cancer imaging agent TLX591-Px, commercially known as Illuccix.
What they said: Managing director and group CEO, Dr Christian Behrenbruch, said: “Telix’s Precision Medicine business delivered excellent sequential growth in Q4 2025, driven in part by the successful launch of Gozellix. This revenue growth outpaced a 3% increase in dose volumes, demonstrating the positive impact of our two-product strategy on market share and pricing.”
The source: Telix Pharmaceuticals
